Cargando…

Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology

BACKGROUND: Breast cancer is the most common malignancy to spread to the orbit and periorbit, and the invasive lobular carcinoma (ILC) histologic subtype of breast cancer has been reported to form these ophthalmic metastases (OM) more frequently than invasive ductal carcinomas (IDC). We herein repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Blohmer, Martin, Zhu, Li, Atkinson, Jennifer M., Beriwal, Sushil, Rodríguez-López, Joshua L., Rosenzweig, Margaret, Brufsky, Adam M., Tseng, George, Lucas, Peter C., Lee, Adrian V., Oesterreich, Steffi, Jankowitz, Rachel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318761/
https://www.ncbi.nlm.nih.gov/pubmed/32586354
http://dx.doi.org/10.1186/s13058-020-01309-3
_version_ 1783550927507030016
author Blohmer, Martin
Zhu, Li
Atkinson, Jennifer M.
Beriwal, Sushil
Rodríguez-López, Joshua L.
Rosenzweig, Margaret
Brufsky, Adam M.
Tseng, George
Lucas, Peter C.
Lee, Adrian V.
Oesterreich, Steffi
Jankowitz, Rachel C.
author_facet Blohmer, Martin
Zhu, Li
Atkinson, Jennifer M.
Beriwal, Sushil
Rodríguez-López, Joshua L.
Rosenzweig, Margaret
Brufsky, Adam M.
Tseng, George
Lucas, Peter C.
Lee, Adrian V.
Oesterreich, Steffi
Jankowitz, Rachel C.
author_sort Blohmer, Martin
collection PubMed
description BACKGROUND: Breast cancer is the most common malignancy to spread to the orbit and periorbit, and the invasive lobular carcinoma (ILC) histologic subtype of breast cancer has been reported to form these ophthalmic metastases (OM) more frequently than invasive ductal carcinomas (IDC). We herein report our single academic institution experience with breast cancer OM with respect to anatomical presentation, histology (lobular vs. ductal), treatment, and survival. METHODS: We employed the natural language processing platform, TIES (Text Information Extraction System), to search 2.3 million de-identified patient pathology and radiology records at our institution in order to identify patients with OM secondary to breast cancer. We then compared the resultant cohort, the “OM cohort,” to two other representative metastatic breast cancer patient (MBC) databases from our institution. Histological analysis of selected patients was performed. RESULTS: Our TIES search and manual refinement ultimately identified 28 patients who were diagnosed with breast cancer between 1995 and 2016 that subsequently developed OM. Median age at diagnosis was 54 (range 28–77) years of age. ER, PR, and HER2 status from the 28 patients with OM did not differ from other patients with MBC from our institution. The relative proportion of patients with ILC was significantly higher in the OM cohort (32.1%) than in other MBC patients in our institution (11.3%, p = 0.007). Median time to first OM in the OM cohort was 46.7 months, and OM were the second most frequent first metastases after bony metastases. After diagnosis of the first distant metastasis of any kind, median survival of patients with ILC (21.4 months) was significantly shorter than that of patients with IDC (55.3 months, p = 0.03). Nine patients developed bilateral OM. We observed a significant co-occurrence of OM and central nervous system metastases (p = 0.0053). The histological analysis revealed an interesting case in which the primary tumor was of a mixed ILC/IDC subtype, while only ILC was present in the OM. CONCLUSIONS: OM from breast cancer are illustrative of the difference in metastatic behavior of ILC versus IDC and should be considered when treating patients with ILC, especially in those with complaints of visual acuity changes.
format Online
Article
Text
id pubmed-7318761
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73187612020-06-29 Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology Blohmer, Martin Zhu, Li Atkinson, Jennifer M. Beriwal, Sushil Rodríguez-López, Joshua L. Rosenzweig, Margaret Brufsky, Adam M. Tseng, George Lucas, Peter C. Lee, Adrian V. Oesterreich, Steffi Jankowitz, Rachel C. Breast Cancer Res Research Article BACKGROUND: Breast cancer is the most common malignancy to spread to the orbit and periorbit, and the invasive lobular carcinoma (ILC) histologic subtype of breast cancer has been reported to form these ophthalmic metastases (OM) more frequently than invasive ductal carcinomas (IDC). We herein report our single academic institution experience with breast cancer OM with respect to anatomical presentation, histology (lobular vs. ductal), treatment, and survival. METHODS: We employed the natural language processing platform, TIES (Text Information Extraction System), to search 2.3 million de-identified patient pathology and radiology records at our institution in order to identify patients with OM secondary to breast cancer. We then compared the resultant cohort, the “OM cohort,” to two other representative metastatic breast cancer patient (MBC) databases from our institution. Histological analysis of selected patients was performed. RESULTS: Our TIES search and manual refinement ultimately identified 28 patients who were diagnosed with breast cancer between 1995 and 2016 that subsequently developed OM. Median age at diagnosis was 54 (range 28–77) years of age. ER, PR, and HER2 status from the 28 patients with OM did not differ from other patients with MBC from our institution. The relative proportion of patients with ILC was significantly higher in the OM cohort (32.1%) than in other MBC patients in our institution (11.3%, p = 0.007). Median time to first OM in the OM cohort was 46.7 months, and OM were the second most frequent first metastases after bony metastases. After diagnosis of the first distant metastasis of any kind, median survival of patients with ILC (21.4 months) was significantly shorter than that of patients with IDC (55.3 months, p = 0.03). Nine patients developed bilateral OM. We observed a significant co-occurrence of OM and central nervous system metastases (p = 0.0053). The histological analysis revealed an interesting case in which the primary tumor was of a mixed ILC/IDC subtype, while only ILC was present in the OM. CONCLUSIONS: OM from breast cancer are illustrative of the difference in metastatic behavior of ILC versus IDC and should be considered when treating patients with ILC, especially in those with complaints of visual acuity changes. BioMed Central 2020-06-26 2020 /pmc/articles/PMC7318761/ /pubmed/32586354 http://dx.doi.org/10.1186/s13058-020-01309-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Blohmer, Martin
Zhu, Li
Atkinson, Jennifer M.
Beriwal, Sushil
Rodríguez-López, Joshua L.
Rosenzweig, Margaret
Brufsky, Adam M.
Tseng, George
Lucas, Peter C.
Lee, Adrian V.
Oesterreich, Steffi
Jankowitz, Rachel C.
Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology
title Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology
title_full Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology
title_fullStr Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology
title_full_unstemmed Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology
title_short Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology
title_sort patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318761/
https://www.ncbi.nlm.nih.gov/pubmed/32586354
http://dx.doi.org/10.1186/s13058-020-01309-3
work_keys_str_mv AT blohmermartin patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology
AT zhuli patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology
AT atkinsonjenniferm patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology
AT beriwalsushil patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology
AT rodriguezlopezjoshual patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology
AT rosenzweigmargaret patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology
AT brufskyadamm patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology
AT tsenggeorge patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology
AT lucaspeterc patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology
AT leeadrianv patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology
AT oesterreichsteffi patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology
AT jankowitzrachelc patienttreatmentandoutcomeafterbreastcancerorbitalandperiorbitalmetastasesacomprehensivecaseseriesincludinganalysisoflobularversusductaltumorhistology